You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
The skin cancer diagnostics company said it delivered 5 percent fewer DecisionDx-Melanoma test results in Q4 2020 than in the previous year's fourth quarter.
For the three months ended Dec. 31, 2020, the La Jolla, California-based firm posted $2.1 million in revenues, up from $1.6 million in Q4 2019.
DermTech said its gene expression-based Pigmented Lesion Assay for the early detection of melanoma is now available as an in-network option for BCBSTX members.
The company said it intends to use the net proceeds from the offering to fund further commercialization of its clinical tests, among other uses.
The investment bank gave a price target of $3.33 per share for Aspira, which focuses on women's health, and $11.97 for dermatology firm DermTech.
The skin cancer test developer reported total revenues of $14.8 million compared to $3.7 in Q3 2018, beating the Wall Street expectation of $9.5 million.
The pilot study with the Mayo Clinic is the final step before SkylineDx commences a US trial next year for its molecular test for primary cutaneous melanoma.
The company reported $10.7 million in total revenues for the quarter and said test report volume for its DecisionDx-Melanoma test grew 27 percent.
The company markets two tests for skin cancer, including DecisionDx-Melanoma for identifying high-risk Stage I and II cutaneous melanoma patients.